Insys Therapeut (NASDAQ: INSY) reported Q2 EPS of $0.58, $0.28 better than the analyst estimate of $0.30. Revenue for the quarter came in at $55.7 million versus the consensus estimate of $52.77 million. Insys plans to file IND for Sildenafel for ED in 2014.

For earnings history and earnings-related data on Insys Therapeut (INSY) click here.